Prostate Cancer Statistics – 2025

The American Cancer Society annually estimates the number of new cancer cases and deaths in the United States. It compiles data on

cancer occurrence and outcomes. In 2025, over two million cancer cases and six hundred thousand cancer deaths are projected. The incidence of prostate cancer spiked during the early 1990s due to PSA testing, and identification declined from 2007 to 2013 due to the United States Preventive Services Task Force (USPSTF) recommendations against PSA screening. The incidence has leveled off and remained stable through 2021.

Sixty percent of men with low-risk disease are managed with active surveillance versus 9% with intermediate-risk disease.

2025 Prostate Cancer Screening, Incidence, and Mortality Rates

PSA testing remains underused today. Only 38% of White men and 34% of Black men over 50 years old are being tested. Because of the high incidence of prostate cancer in Black men (68% higher than White men, two times higher than American Indian/Alaskan Native and Hispanic men, and three times higher than Asian American/Pacific Islander men), Black men should start screening earlier at age 45 years and be screened frequently. This is especially important because Black men have a 2-fold higher mortality rate from prostate cancer than White men.

The good news is that there has been an increase in the 5-year survival rate. From 1975-77, this rate was 68%; currently, the 5-year survival rate is 97%. The prostate cancer death rate in 2022 was 52% lower than in 1993, but it has plateaued since 2012.

The continued reduction in cancer incidence and mortality rates will require investment in cancer prevention and access to equitable treatment.

Siegel, RL et al Cancer J Clin 2025:10-45